|
WO2018000047A1
|
|
Method of treating immunoglobulin light chain amyloidosis
|
|
WO2016086261A1
|
|
4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
|
|
EP2379510A1
|
|
Quinazolinone compounds
|
|
AU2008331439A1
|
|
Compounds for therapy and diagnosis
|
|
WO2008074068A1
|
|
Substituted quinoline derivatives as antiamyloidogeneic agents
|
|
AU2007262670A1
|
|
Method of treatment of glioma brain tumour
|
|
CA2711638A1
|
|
3-substituted-8-hydroxypyridino[1,2-a]pyrimidin-4-one compounds and their use in treating retinal degenerative diseases
|
|
BRPI0710737A2
|
|
use of compounds pb-10 33 useful for the treatment of age-related macular degeneration (amd) as well as said compounds
|
|
AU2005229161A1
|
|
Neurologically-active compounds
|
|
WO2005095360A1
|
|
Neurologically-active compounds
|
|
CN101018772A
|
|
Neurologically-active compounds
|
|
AU2004226876A1
|
|
Treatment of neurological conditions
|
|
BR0315008A
|
|
Neurologically Active Compounds
|
|
AU2003265740A1
|
|
Neurologically-active compounds
|
|
AU2002951865A0
|
|
Compound iii
|
|
AU2002951868A0
|
|
Compound i
|
|
AU2002951866A0
|
|
Compound iv
|
|
AU2002951867A0
|
|
Compound vi
|
|
AU2002951863A0
|
|
Compound v
|
|
AU2002951864A0
|
|
Compound ii
|
